

Supplemental Table 1. YKL-40 expression, radiation and anti-angiogenic therapy, and disease survival in patients with GBM.

| Case | YKL-40 level ^a | Radiotherapy | Anti-angiogenic drugs (bevacizumab) | Survival (months) |
|------|---------------------------|--------------|--|----------------------|
| 1 | L | Yes | Yes | 38 |
| 2 | L | Yes | No | >13* |
| 3 | L | Yes | No | 6 |
| 4 | L | Yes | Yes | 10 |
| 5 | L | Yes | Yes | 40 |
| 6 | H | Yes | Yes | 15 |
| 7 | H | Yes | No | 3 |
| 8 | H | No | No | 1 |
| 9 | H | Yes | No | 1 |
| 10 | H | No | No | 0 ⁺ |

^aH and L indicate high and low levels of YKL-40, respectively; *Survival data not available after 13 months; ⁺Ten-day survival.